GSK3B and non-small cell lung carcinoma: For example, in non-small cell lung cancer (NSCLC), GSK-3β expression is associated with cervical lymph node metastases, poor differentiation, advanced stage, late diagnosis, and worse survival, while inhibiting GSK-3 can result in cancer cell apoptosis and cell cycle arrest (99, 100).